To Evaluate the Effect of MCS速 in Prostate Cancer Prevention
To evaluate the effect of MCS速 compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of treatment.
Prostate Cancer
DRUG: Placebo|DRUG: MCS速
Cumulative biopsy-detectable prostate cancer rate, Week 104 (Month 24)
To evaluate the effect of MCS速 compared with placebo in reducing the risk of biopsy-detectable prostate cancer in high-risk subjects after 104 weeks (24 months) of treatment.